ArticleBritish journal of clinical pharmacology2003
Discontinuation and switching of therapy after initiation of lipid-lowering drugs: the effects of comorbidities and patient characteristics.
Article in British journal of clinical pharmacology, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Prevalence of statin intolerance: a meta-analysis.European heart journal · 2022 · on this mapPooled it
- Predictors of nonadherence to statins: a systematic review and meta-analysis.The Annals of pharmacotherapy · 2010Pooled it
- Clinician prescription of lipid-lowering drugs and achievement of treatment goals in patients with newly diagnosed type 2 diabetes mellitus.BMJ open diabetes research & care · 2021Trial
- Clinical Characteristics of Patients With Statin Discontinuation in Korea: A Nationwide Population-Based Study.Journal of lipid and atherosclerosis · 2024Article
- Determinants of Non-Adherence to the Medications for Dyslipidemia: A Systematic Review.Patient preference and adherence · 2021Review
- Factors Associated With Regorafenib Adherence With Metastatic Colorectal Cancer.Patient preference and adherence · 2019Article
- Ten-year trends in antiretroviral therapy persistence among US Medicaid beneficiaries.AIDS (London, England) · 2017Article
- Patients who discontinued statin treatment: a protocol for cohort study using primary care data.BMJ open · 2015Observational
- Lifestyle factors as predictors of nonadherence to statin therapy among patients with and without cardiovascular comorbidities.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2014 · on this mapObservational
- Does the use of an electronic reminder device with or without counseling improve adherence to lipid-lowering treatment? The results of a randomized controlled trial.Frontiers in pharmacology · 2013Article
- Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia.PharmacoEconomics · 2007Article
- Statin-macrolide interaction risk: a population-based study throughout a general practice database.European journal of clinical pharmacology · 2005Article
- Predictors of first-year statin medication discontinuation: A cohort study.Journal of clinical lipidologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsTo evaluate the effects of comorbidities and patient characteristics on treatment continuation among patients starting their first course of lipid-lowering drug (LLD) therapy.
methodsWithin the UK General Practice Research Database (GPRD), we identified 22 408 patients who started LLD therapy due to coronary heart disease, hyperlipidaemia, or other atherosclerotic diseases, and who received > or = two prescriptions for LLD between January 1 1990 and December 31 1997. Differences in potential predictors of treatment continuation between patients who continued, and patients who discontinued/switched lipid-lowering therapy within 1 year after treatment initiation were compared by fitting multivariate logistic regression models. The effects of baseline characteristics on treatment continuation after switching of LLDs were also analysed.
resultsDiscontinuation/switching of lipid-lowering therapy was common during the study period, especially among patients who received nonstatin, nonfibrate LLDs (log-rank test P = 0.0001). Statin use, more frequent physician visits, more concurrent cardiovascular medications, diabetes, and fewer noncardiovascular medications were associated with treatment continuation of LLDs. Among patients who switched therapy, prescribing of a statin as the substituted LLD, more concurrent cardiovascular medications, and later treatment switching were related to a higher probability of treatment continuation after switching LLDs.
conclusionsTreatment continuation after initiation or switching of lipid-lowering therapy largely increased with concomitant cardiovascular comorbidities, and more health care utilization, and is more common for statins than for other LLDs. Practice guidelines, patient education, and quality of care assessment for lipid-lowering therapy should emphasize factors that predispose patients to discontinuation/switching, in an effort to optimize the choice of therapeutic regimens and to improve patient adherence.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.